Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias?

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Recent discoveries have identified key molecular events in the pathogenesis of acute promyelocytic leukemia (APL), caused by chromosomal rearrangements of the transcription factor RAR (resulting in a fusion protein with the product of other cellular genes, such as PML). Oligomerization of RAR, through a self-association domain present in PML, imposes an altered interaction with transcriptional co-regulators (NCoR/SMRT). NCoR/SMRT are responsible for recruitment of histone deacetylases (HDACs), which is required for transcriptional repression of PML-RAR target genes, and for the transforming potential of the fusion protein. Oligomerization and altered recruitment of HDACs are also responsible for transformation by the fusion protein AML1-ETO, extending these mechanisms to other forms of acute myeloid leukemias (AMLs) and suggesting that HDAC is a common target for myeloid leukemias. Strikingly, AML1-ETO expression blocks retinoic acid (RA) signaling in hematopoietic cells, suggesting that interference with the RA pathway (genetically altered in APL) by HDAC recruitment may be a common theme in AMLs. Treatment of APLs with RA, and of other AMLs with RA plus HDAC inhibitors (HDACi), results in myeloid differentiation. Thus, activation of the RA signaling pathway and inhibition of HDAC activity might represent a general strategy for the differentiation treatment of myeloid leukemias.

Original languageEnglish
Pages (from-to)3110-3115
Number of pages6
JournalOncogene
Volume20
Issue number24 REV. ISS. 3
DOIs
Publication statusPublished - May 28 2001

Fingerprint

Histone Deacetylases
Acute Myeloid Leukemia
Tretinoin
Acute Promyelocytic Leukemia
Myeloid Leukemia
Proteins
Oncogenes
Transcription Factors
Genes

Keywords

  • Acute myeloid leukemias
  • Differentiation therapy
  • Histone deacetylases
  • PML-RAR

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Histone deacetylases : A common molecular target for differentiation treatment of acute myeloid leukemias? / Minucci, Saverio; Nervi, Clara; Lo Coco, Francesco; Pelicci, Pier Giuseppe.

In: Oncogene, Vol. 20, No. 24 REV. ISS. 3, 28.05.2001, p. 3110-3115.

Research output: Contribution to journalArticle

@article{99873e5fe36c40a2afb7643919d3081d,
title = "Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias?",
abstract = "Recent discoveries have identified key molecular events in the pathogenesis of acute promyelocytic leukemia (APL), caused by chromosomal rearrangements of the transcription factor RAR (resulting in a fusion protein with the product of other cellular genes, such as PML). Oligomerization of RAR, through a self-association domain present in PML, imposes an altered interaction with transcriptional co-regulators (NCoR/SMRT). NCoR/SMRT are responsible for recruitment of histone deacetylases (HDACs), which is required for transcriptional repression of PML-RAR target genes, and for the transforming potential of the fusion protein. Oligomerization and altered recruitment of HDACs are also responsible for transformation by the fusion protein AML1-ETO, extending these mechanisms to other forms of acute myeloid leukemias (AMLs) and suggesting that HDAC is a common target for myeloid leukemias. Strikingly, AML1-ETO expression blocks retinoic acid (RA) signaling in hematopoietic cells, suggesting that interference with the RA pathway (genetically altered in APL) by HDAC recruitment may be a common theme in AMLs. Treatment of APLs with RA, and of other AMLs with RA plus HDAC inhibitors (HDACi), results in myeloid differentiation. Thus, activation of the RA signaling pathway and inhibition of HDAC activity might represent a general strategy for the differentiation treatment of myeloid leukemias.",
keywords = "Acute myeloid leukemias, Differentiation therapy, Histone deacetylases, PML-RAR",
author = "Saverio Minucci and Clara Nervi and {Lo Coco}, Francesco and Pelicci, {Pier Giuseppe}",
year = "2001",
month = "5",
day = "28",
doi = "10.1038/sj.onc.1204336",
language = "English",
volume = "20",
pages = "3110--3115",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "24 REV. ISS. 3",

}

TY - JOUR

T1 - Histone deacetylases

T2 - A common molecular target for differentiation treatment of acute myeloid leukemias?

AU - Minucci, Saverio

AU - Nervi, Clara

AU - Lo Coco, Francesco

AU - Pelicci, Pier Giuseppe

PY - 2001/5/28

Y1 - 2001/5/28

N2 - Recent discoveries have identified key molecular events in the pathogenesis of acute promyelocytic leukemia (APL), caused by chromosomal rearrangements of the transcription factor RAR (resulting in a fusion protein with the product of other cellular genes, such as PML). Oligomerization of RAR, through a self-association domain present in PML, imposes an altered interaction with transcriptional co-regulators (NCoR/SMRT). NCoR/SMRT are responsible for recruitment of histone deacetylases (HDACs), which is required for transcriptional repression of PML-RAR target genes, and for the transforming potential of the fusion protein. Oligomerization and altered recruitment of HDACs are also responsible for transformation by the fusion protein AML1-ETO, extending these mechanisms to other forms of acute myeloid leukemias (AMLs) and suggesting that HDAC is a common target for myeloid leukemias. Strikingly, AML1-ETO expression blocks retinoic acid (RA) signaling in hematopoietic cells, suggesting that interference with the RA pathway (genetically altered in APL) by HDAC recruitment may be a common theme in AMLs. Treatment of APLs with RA, and of other AMLs with RA plus HDAC inhibitors (HDACi), results in myeloid differentiation. Thus, activation of the RA signaling pathway and inhibition of HDAC activity might represent a general strategy for the differentiation treatment of myeloid leukemias.

AB - Recent discoveries have identified key molecular events in the pathogenesis of acute promyelocytic leukemia (APL), caused by chromosomal rearrangements of the transcription factor RAR (resulting in a fusion protein with the product of other cellular genes, such as PML). Oligomerization of RAR, through a self-association domain present in PML, imposes an altered interaction with transcriptional co-regulators (NCoR/SMRT). NCoR/SMRT are responsible for recruitment of histone deacetylases (HDACs), which is required for transcriptional repression of PML-RAR target genes, and for the transforming potential of the fusion protein. Oligomerization and altered recruitment of HDACs are also responsible for transformation by the fusion protein AML1-ETO, extending these mechanisms to other forms of acute myeloid leukemias (AMLs) and suggesting that HDAC is a common target for myeloid leukemias. Strikingly, AML1-ETO expression blocks retinoic acid (RA) signaling in hematopoietic cells, suggesting that interference with the RA pathway (genetically altered in APL) by HDAC recruitment may be a common theme in AMLs. Treatment of APLs with RA, and of other AMLs with RA plus HDAC inhibitors (HDACi), results in myeloid differentiation. Thus, activation of the RA signaling pathway and inhibition of HDAC activity might represent a general strategy for the differentiation treatment of myeloid leukemias.

KW - Acute myeloid leukemias

KW - Differentiation therapy

KW - Histone deacetylases

KW - PML-RAR

UR - http://www.scopus.com/inward/record.url?scp=0035962644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035962644&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1204336

DO - 10.1038/sj.onc.1204336

M3 - Article

C2 - 11420727

AN - SCOPUS:0035962644

VL - 20

SP - 3110

EP - 3115

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 24 REV. ISS. 3

ER -